# Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

> **NCT02303899** · PHASE2 · COMPLETED · sponsor: **Istituto Clinico Humanitas** · enrollment: 22 (actual)

## Conditions studied

- Mesothelioma, Malignant

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT02303899
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-12
- **Final completion:** 2017-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303899, "Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02303899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*